Ivo Vincetić

Dr. Ivo Vincetić

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Medicina Fluminensis
Verified
Journal Article
Open access
PDF file
IVIvo Vincetić
Ivo Vincetić
MVMarko Vincetić
Marko Vincetić
DMDomagoj Matijević
Domagoj Matijević
Aim: The absence of the inferior vena cava (IVC) is a rare abnormality reported in less than 1% of the population. The collateral veins are enlarged with agenesis IVC, enabling blood transport to the superior vena cava. IVC agenesis (IVCA) may predispose to venous hypertension and complications, including thromboembolism. Case report: We present a case of a 20-year-old female patient with syncope who came to the emergency ambulance. She had profuse perspiration, and she lost 12 kg of body weight in one month. Under the suspicion of pulmonary thromboembolism, a CT (computed tomography) angiography of the pulmonary arteries showed a retrosternal para-aortic hypovascular soft tissue formation with a diameter of 30x40x85 mm. Laboratory findings also confirmed higher thyroid hormone values. Immunohyperthyroidism was diagnosed. A venous phase of CT angiograpy scan of the thorax was performed which showed that para-aortic hypovascular soft-active formation is the thymus, but an incidental finding was also discovered (Figure 1.). There was no representation of the inferior v. cava in the area from the renal veins to the heart, and the dominant azygos and hemiazygos v. were visible (Figure 2.). Hemiazygos vein merges into the azygos vein in the thorax area (Figure 3.). All the above corresponds primarily to the anatomical variant of congenital absence of v. cava inferior. Conclusion: IVCA is a significant but highly under recognized cause of unprovoked DVT (deep vein thrombosis) of the lower extremities in the young population without additional risk factors. Therefore, in unclear cases of unprovoked deep vein thrombosis of the lower extremities in the younger population, this cause should also be considered, and accordingly, the necessary diagnostic evaluation should be performed, which includes imaging for vascular anomalies along with a thrombophilic screen. Treatment is mainly conservative and may require lifelong anticoagulation therapy.

1 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
IVIvo Vincetić
Ivo Vincetić
ASAna Stupin
Ana Stupin
ITIvana Tolj
Ivana Tolj
Ivana JukićIvana Jukić
Ivana Jukić
IDInes Drenjancevic
Ines Drenjancevic
MSMarko Stupin
Marko Stupin
Prehypertension, defined as blood pressure of 120–139/80–89 mmHg, affects approximately 36–38% of adults worldwide and is associated with a substantially increased risk of cardiovascular disease, stroke, and coronary heart disease. Beyond being a transitional stage toward overt hypertension, prehypertension represents a biologically active vascular state in which early vascular injury is already evident. Endothelial dysfunction is considered the earliest detectable vascular abnormality in prehypertension and is characterized by reduced nitric oxide bioavailability, endothelial nitric oxide synthase (eNOS) uncoupling, and increased asymmetric dimethylarginine levels. These alterations are accompanied by endothelial activation, reflected by enhanced expression of adhesion molecules and endothelin-1, as well as impaired endothelial progenitor cell function with a reported threshold effect at systolic blood pressure of 130 mmHg. In parallel, prehypertensive individuals exhibit increased arterial stiffness and microvascular abnormalities, including systemic capillary rarefaction and retinal microvascular alterations. Oxidative stress, driven mainly by NADPH oxidase activation and eNOS uncoupling, appears to be a central mechanism linking elevated blood pressure with endothelial dysfunction and progressive vascular damage. However, the temporal relationship between oxidative imbalance, endothelial dysfunction, and blood pressure progression remains unclear. It is still uncertain whether oxidative stress initiates vascular impairment or primarily accelerates already established endothelial injury. Further prospective studies are needed to define the vascular trajectory of prehypertension, clarify its prognostic relevance, and identify whether early vascular alterations represent therapeutic targets for cardiovascular prevention. By integrating current evidence, this review examines endothelial dysfunction in prehypertension, with particular attention to oxidative stress and its interactions with NO signaling, endothelial activation, and vascular remodeling.